Key facts
- Newrite Medical’s last known valuation is $32.7M (Aug 2018).
- It has raised $330.9M; the latest was Later Stage VC ($145.0M) in Apr 2026.
- Notable investors include Shenzhen Capital Group, Co-Stone Capital, Highlight Capital, Sichuan Venture Capital, Chengdu Venture Capital Group — 28 tracked in total.
- Status: Privately Held (backing).
Investors
28+- ·The complete investor list — 28 names
- ·Watchlist + deal alerts for Newrite Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Newrite Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Newrite Medical
Developer of targeted therapeutic and diagnostic agents for nuclear medicine applications. The company offers radiopharmaceutical development, isotope production, and radioligand therapy technologies, enabling healthcare providers to perform precision imaging and minimally invasive treatment of cancer and related diseases.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2016
- Employees
- 90
- Website
- nrtmedtech.com/
- Ownership
- Privately Held (backing)
Newrite Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Newrite Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Newrite Medical in its N-PORT filings yet. We sweep new filings monthly.